Investors
INVESTORS
2018-10-31MMMM D, YYYY

Third Quarter 2018 Results

At a glance

Olivier Brandicourt
2018-10-31MMMM D, YYYY

Olivier Brandicourt, CEO, comments on Q3 2018 results

2018 Half Year Financial Report

Half-Year Financial Report 2018

Upcoming events

  • 2019-01-08
  • 2019-02-07
Olivier Brandicourt
Broker Conferences

Bank of America ML Global Healthcare Conference

2018-09-14MMMM D, YYYY
2017 Integrated Report

2017 Integrated Report

Contact the Investor Relations team

54 rue La Boétie
75008 Paris FRANCE
France +33 (0)1 53 77 45 45 • ir@sanofi.com
United States +1 908 981 5560

Press releases

[Feed JS]

In-depth reading

Young boy on a bicycle

New franchise Rare Blood Disorders

In 2018, Sanofi created a leading platform in Rare Blood Disorders through a series of three strategic deals: we obtained global rights for fitusiran, acquired Bioverativ and Ablynx. These operations should expand Sanofi’s presence in Specialty Care and further strengthen our Research & Development pipeline.
All financial results going back to 2013
FINANCIAL RESULTS

All financial results going back to 2013

Sustaining Innovation Day
INVESTOR PRESENTATIONS

Sustaining Innovation Day

2017-12-13MMMM D, YYYY
INVESTOR PRESENTATIONS

IR conference call on Odyssey Outcomes

2018-03-10MMMM D, YYYY
sanofi_ir_2017_ddr_bloc_vertical

Annual Report on Form 20-F 2017

Individual shareholders

Direct access to Individual shareholders - Welcome to Sanofi

Access your dedicated section

2017 Sanofi Brochure

Shareholder Handbook 2018

Letter to shareholders September 2018

Letter to shareholders September 2018

Sanofi IR app on different devices

SANOFI IR The Investor Relations app

SANOFI IR provides financial information with direct access to key news, events, publications and a dedicated section for individual shareholders
Download the IR app on the App Store Get the IR app on Google Play